Finn, R. S., Press, M. F., Dering, J., Arbushites, M., Koehler, M., Oliva, C., . . . Di Leo, A. (2009). Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer. American Society of Clinical Oncology.
シカゴスタイル引用形Finn, Richard S., Michael F. Press, Judy Dering, Michael Arbushites, Maria Koehler, Cristina Oliva, Lisa S. Williams, , Angelo Di Leo. Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer. American Society of Clinical Oncology, 2009.
MLA引用形式Finn, Richard S., et al. Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer. American Society of Clinical Oncology, 2009.